Activity of Imatinib Mesylate in Metastatic Anorectal Melanoma: A Case Report
详细信息 查看全文
- 作者：Samia Arifi (1) (2)
El Mehdi Tazi (1)
Omar El Mesbahi (2)
Hassan Errihani (1) - 刊名：Journal of Gastrointestinal Cancer
- 出版年：2012
- 出版时间：September 2012
- 年：2012
- 卷：43
- 期：1-supp
- 页码：145-147
- 全文大小：124KB
- 参考文献：1. Yeh JJ, Weiser MR, Shia J, Hwu WJ. Response of stage IV anal mucosal melanoma to chemotherapy. Lancet Oncol. 2005;6(6):438鈥?. CrossRef
2. Natarajan N, Telang S, Miller D, Chesney J. Novel immunotherapeutic agents and small molecule antagonists of signalling kinases for the treatment of metastatic melanoma. Drugs. 2011;71(10):1233鈥?0. CrossRef
3. Carvajal RD, Antonescu CR, Wolchok JD, Chapman PB, Roman RA, Teitcher J, et al. KIT as a therapeutic target in metastatic melanoma. JAMA. 2011;305(22):2327鈥?4. CrossRef
4. Hodi FS, O鈥橠ay SJ, McDermott DF, et al. Improved survival with ipilimumab in patients with metastatic melanoma. N Engl J Med. 2010;363:711鈥?3. Erratum, N Engl J Med 2010; 363:1290. CrossRef
5. Robert C, Thomas L, Bondarenko I, O'Day S, Weber J, Garbe C, et al. Ipilimumab plus dacarbazine for previously untreated metastatic melanoma. N Engl J Med. 2011;364(26):2517鈥?6. CrossRef
6. Chapman PB, Hauschild A, Robert C, Haanen JB, Ascierto P, et al. Improved survival with vemurafenib in melanoma with BRAF V600E mutation. N Engl J Med. 2011;364(26):2507鈥?6. CrossRef
7. Ribas A, Kim KB, Schuchter LM, et al. BRIM-2: an open-label, multicenter phase II study of vemurafenib in previously treated patients with BRAFV600E mutation-positive melanoma. J Clin Oncol. 2011;29(Suppl):8509. Abstract.
8. Curtin JA, Busam K, Pinkel D, Bastian BC. Somatic activation of KIT in distinct subtypes of melanoma. J Clin Oncol. 2006;24(26):4340鈥?. CrossRef
9. Antonescu CR, Busam KJ, Francone TD, Wong GC, Guo T, Agaram NP, et al. L576P KIT mutation in anal melanomas correlates with KIT protein expression and is sensitive to specific kinase inhibition. Int J Cancer. 2007;121(2):257鈥?4. CrossRef
10. McDonnell K, Betz B, Fullen D, Lao CD. V559A and N822I double KIT mutant melanoma with predictable response to imatinib? Pigment Cell Melanoma Res. 2011;24(2):390鈥?. CrossRef
11. Lutzky J, Bauer J, Bastian BC. Dose-dependent, complete response to imatinib of a metastatic mucosal melanoma with a K642E KIT mutation. Pigment Cell Melanoma Res. 2008;21(4):492鈥?. CrossRef
12. Ugurel S, Hildenbrand R, Zimpfer A, et al. Lack of clinical efficacy of imatinib in metastatic melanoma. Br J Cancer. 2005;92(8):1398鈥?05. CrossRef
13. Atkins MB, Prieto V. Multicenter phase II trial of high-dose imatinib mesylate in metastatic melanoma significant toxicity with no clinical efficacy. Cancer. 2006;106(9):2005鈥?1. CrossRef
14. Woodman SE, Davies MA. Targeting KIT in melanoma: a paradigm of molecular medicine and targeted therapeutics. Biochem Pharmacol. 2010;80(5):568鈥?4. CrossRef
15. Gramza AW, Corless CL, Heinrich MC. Resistance to tyrosine kinase inhibitors in gastrointestinal stromal tumors. Clin Cancer Res. 2009;15(24):7510鈥?. CrossRef - 作者单位：Samia Arifi (1) (2)
El Mehdi Tazi (1)
Omar El Mesbahi (2)
Hassan Errihani (1)
1. Department of Medical Oncology, National Institute of Medical Oncology, Rabat, Morocco
2. Department of Medical Oncology, Hassan II University Hospital, Route Sidi Harazem, 30000, Fez, Morocco - ISSN：1941-6636
文摘